<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>&#x415;&#x432;&#x440;&#x43E;&#x43F;&#x435;&#x439;&#x441;&#x43A;&#x438; &#x43F;&#x440;&#x430;&#x432;&#x435;&#x43D; &#x43F;&#x440;&#x435;&#x433;&#x43B;&#x435;&#x434;</provider_name><provider_url>https://evropeiskipravenpregled.eu</provider_url><author_name>Hristo Kirilov</author_name><author_url>https://evropeiskipravenpregled.eu/author/hristo-kirilov/</author_url><title>Limitations of Parallel Trade with Pharmaceuticals in the Practice of the European Commission, CJEU and the Bulgarian Commission for Protection of Competition - &#x415;&#x432;&#x440;&#x43E;&#x43F;&#x435;&#x439;&#x441;&#x43A;&#x438; &#x43F;&#x440;&#x430;&#x432;&#x435;&#x43D; &#x43F;&#x440;&#x435;&#x433;&#x43B;&#x435;&#x434;</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content"&gt;&lt;a href="https://evropeiskipravenpregled.eu/25-29/"&gt;Limitations of Parallel Trade with Pharmaceuticals in the Practice of the European Commission, CJEU and the Bulgarian Commission for Protection of Competition&lt;/a&gt;&lt;/blockquote&gt;
&lt;script type='text/javascript'&gt;
&lt;!--//--&gt;&lt;![CDATA[//&gt;&lt;!--
		/*! This file is auto-generated */
		!function(d,l){"use strict";var e=!1,o=!1;if(l.querySelector)if(d.addEventListener)e=!0;if(d.wp=d.wp||{},!d.wp.receiveEmbedMessage)if(d.wp.receiveEmbedMessage=function(e){var t=e.data;if(t)if(t.secret||t.message||t.value)if(!/[^a-zA-Z0-9]/.test(t.secret)){var r,a,i,s,n,o=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),c=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]');for(r=0;r&lt;c.length;r++)c[r].style.display="none";for(r=0;r&lt;o.length;r++)if(a=o[r],e.source===a.contentWindow){if(a.removeAttribute("style"),"height"===t.message){if(1e3&lt;(i=parseInt(t.value,10)))i=1e3;else if(~~i&lt;200)i=200;a.height=i}if("link"===t.message)if(s=l.createElement("a"),n=l.createElement("a"),s.href=a.getAttribute("src"),n.href=t.value,n.host===s.host)if(l.activeElement===a)d.top.location.href=t.value}}},e)d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",t,!1),d.addEventListener("load",t,!1);function t(){if(!o){o=!0;var e,t,r,a,i=-1!==navigator.appVersion.indexOf("MSIE 10"),s=!!navigator.userAgent.match(/Trident.*rv:11\./),n=l.querySelectorAll("iframe.wp-embedded-content");for(t=0;t&lt;n.length;t++){if(!(r=n[t]).getAttribute("data-secret"))a=Math.random().toString(36).substr(2,10),r.src+="#?secret="+a,r.setAttribute("data-secret",a);if(i||s)(e=r.cloneNode(!0)).removeAttribute("security"),r.parentNode.replaceChild(e,r)}}}}(window,document);
//--&gt;&lt;!]]&gt;
&lt;/script&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://evropeiskipravenpregled.eu/25-29/embed/" width="600" height="338" title="&#x201C;Limitations of Parallel Trade with Pharmaceuticals in the Practice of the European Commission, CJEU and the Bulgarian Commission for Protection of Competition&#x201D; &#x2014; &#x415;&#x432;&#x440;&#x43E;&#x43F;&#x435;&#x439;&#x441;&#x43A;&#x438; &#x43F;&#x440;&#x430;&#x432;&#x435;&#x43D; &#x43F;&#x440;&#x435;&#x433;&#x43B;&#x435;&#x434;" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;</html><description>Eleonora Mateina[1] &#xA0; The purpose of the article is to outline the key aspects of the limitations of parallel trade with pharmaceuticals and to review the most significant decisions of the CJEU dedicated to this topic, i.e. decisions under the joined cases C-2/01 P &#x438; C-3/01 (Bayer/Adalat); case C-277/87 (Sandoz); joined cases C 501/06 P, [&#x2026;]</description></oembed>
